



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



JG-2016

Item No. 41876

CAS Registry No.: 2887480-87-5
Formal Name: 7-chloro-8-ethyl-10-[2-(2-methylpropoxy)ethyl]-benzo[g]pteridine-2,4(3H,10H)-dione
MF: C₁₈H₂₁ClN₄O₃
FW: 376.8
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

JG-2016 is supplied as a solid. A stock solution may be made by dissolving the JG-2016 in the solvent of choice, which should be purged with an inert gas. JG-2016 is sparingly soluble (1-10 mg/ml) in DMSO and slightly soluble (0.1-1 mg/ml) in ethanol.

Description

JG-2016 is an inhibitor of histone acetyltransferase 1 (HAT1; IC₅₀ = 14.8 μM).¹ It is selective for HAT1 over lysine acetyltransferase 2A (KAT2A/GCN5) and p300/CBP-associated factor (PCAF), for which it has no activity, KAT5, KAT6B, and KAT7 (IC₅₀s = >100, >100, and 84.82 μM, respectively), CREB-binding protein (CBP), and p300 (IC₅₀s = 90.41 and 74.25 μM, respectively). JG-2016 (20 μM) reduces acetylation of histone H4 lysine 5 (H4K5) and H4K12 in hTert-HME1 mammary epithelial cells. It reduces the growth of HCC1806 triple-negative breast cancer and A549 lung cancer cells (EC₅₀s = 10.4 and 1.9 μM, respectively). JG-2016 reduces intratumoral H4K12 acetylation in an A549 mouse xenograft model in a dose-dependent manner. It also reduces tumor growth in an A549 mouse xenograft model when administered at doses of 50 and 100 mg/kg once every three days.

Reference

1. Gaddameedi, J.D., Chou, T., Geller, B.S., *et al.* An acetyl-click screening platform identifies small-molecule inhibitors of histone acetyltransferase 1 (HAT1). *J. Med. Chem.* **66**(8), 5774-5801 (2023).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/28/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM